JWH-161
Appearance
From Wikipedia, the free encyclopedia
This is the current revision of this page, as edited by KoIobok (talk | contribs) at 10:08, 6 December 2021 (Added Category:Benzochromenes and Category:Carbazoles). The present address (URL) is a permanent link to this version.
Revision as of 10:08, 6 December 2021 by KoIobok (talk | contribs) (Added Category:Benzochromenes and Category:Carbazoles)
(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)
Chemical
![]() | |
Identifiers | |
---|---|
| |
PubChem CID | |
ChemSpider | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C27H33NO2 |
Molar mass | 403.566 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
JWH-161 is a cannabinoid derivative that was designed by Dr John W. Huffman's team as a hybrid between the dibenzopyran "classical" cannabinoid drugs and the novel indole derivatives, in an attempt to unravel the differences in their binding modes to the CB1 receptor. While retaining structural elements from both families, JWH-161 has a CB1 Ki of 19.0nM, although it was found to be slightly weaker than THC in animal tests.[1]
References[edit]
- ^ Huffman JW, Padgett LW (2005). "Recent developments in the medicinal chemistry of cannabimimetic indoles, pyrroles and indenes". Current Medicinal Chemistry. 12 (12): 1395–411. doi:10.2174/0929867054020864. PMID 15974991.
![]() | This cannabinoid related article is a stub. You can help Wikipedia by expanding it. |
Retrieved from "https://en.wikipedia.org/w/index.php?title=JWH-161&oldid=1058915075"
Hidden categories:
- Articles with short description
- Short description matches Wikidata
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without UNII source
- Drugs missing an ATC code
- Drugs with no legal status
- All stub articles